Industry Overview - The second-quarter earnings season for the drug and biotech sector is in full swing, with major companies like Pfizer, Eli Lilly, Amgen, Gilead Sciences, and Novo Nordisk set to announce results [1] - The earnings season began mid-July with Johnson & Johnson reporting strong results, exceeding estimates for both earnings and sales [1] Company Performance Pfizer (PFE) - Pfizer has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 43.49% [6] - The Zacks Consensus Estimate for second-quarter sales and earnings is $13.78 billion and 58 cents per share, respectively [6] - Higher sales from products like Vyndaqel and Padcev are expected to offset weaker sales from Prevnar and Ibrance [8] Eli Lilly (LLY) - Eli Lilly's performance has been mixed, exceeding earnings expectations in two of the last four quarters, with an average earnings surprise of 6.69% [11] - The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively [11] - Strong demand for Mounjaro and Zepbound is anticipated to drive top-line growth [12] Amgen (AMGN) - Amgen has shown strong performance, beating earnings estimates in each of the last four quarters, with an average earnings surprise of 8.34% [14] - The Zacks Consensus Estimate for second-quarter sales and earnings is $8.86 billion and $5.26 per share, respectively [14] - Sales growth is expected to be driven by products like Evenity and Repatha, despite price declines due to higher rebates [15] Gilead Sciences (GILD) - Gilead's performance has been mixed, with earnings beating estimates in three of the last four quarters, averaging a surprise of 16.48% [17] - The Zacks Consensus Estimate for second-quarter sales and earnings is $6.95 billion and $1.95 per share, respectively [17] - Increased demand for HIV therapies like Biktarvy is expected to boost sales [18] Novo Nordisk (NVO) - Novo Nordisk's performance has been mixed, with earnings beating estimates in one of the last four quarters, delivering an average surprise of 0.02% [20] - The Zacks Consensus Estimate for second-quarter sales and earnings is $11.79 billion and 93 cents per share, respectively [20] - The company lowered its 2025 sales and operating profit growth outlook due to weaker momentum in key markets for its semaglutide-based drugs [21]

Key Takeaways NVO will report Q2 earnings on Aug. 6, with consensus EPS at $0.93 and revenues at $11.79 billion.NVO cut 2025 sales and profit guidance due to weaker U.S. demand for Wegovy and Ozempic.Competition from Eli Lilly and illegal compounded drugs is pressuring NVO's obesity drug sales.Novo Nordisk (NVO) is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.79 ...

Industry Overview - The Auto-Tires-Trucks sector is currently in the second-quarter earnings season, with companies like Tesla, Ford, General Motors, Aptiv, and O'Reilly Automotive reporting quarterly numbers that exceeded earnings estimates [1] - The auto sector's earnings for Q2 2025 are projected to decline by 27.7% year-over-year, with revenues expected to decrease by 6% [2] Market Performance - U.S. vehicle sales showed modest year-over-year growth in Q2, driven by strong demand for gasoline-powered and hybrid vehicles, with a seasonally adjusted annual rate of 15.3 million units in June [4] - Retail vehicle inventory reached 2.16 million units in June, marking a 22.9% increase from June 2024, while average transaction prices rose to $46,233, up $1,400 from the previous year [4] Impact of Tariffs - Higher tariffs on imports initially increased demand among price-sensitive buyers, but as prices stabilized, this momentum began to wane [5] - Elevated operating costs, particularly in R&D for advanced technologies, are likely to have negatively impacted earnings [5] Potential Winners - Companies identified as well-positioned to exceed earnings estimates include Cummins Inc. (CMI), Rivian Automotive, Inc. (RIVN), Lucid Group, Inc. (LCID), and American Axle & Manufacturing Holdings, Inc. (AXL) [3] Company Highlights Cummins Inc. (CMI) - Cummins is the largest engine manufacturer globally, with a strong product lineup and a focus on electrification and clean energy technologies [8][9] - The company has an Earnings ESP of +2.79% and a Zacks Rank of 3, with Q2 earnings and revenues estimated at $4.99 per share and $8.47 billion, respectively [10][11] Rivian Automotive, Inc. (RIVN) - Rivian is targeting budget-conscious consumers with its upcoming R2 and R3 models, with the R2 expected to launch in H1 2026 at a starting price of around $45,000 [12] - The company has an Earnings ESP of +8.53% and a Zacks Rank of 3, with Q2 revenue estimated at $1.26 billion [14] Lucid Group, Inc. (LCID) - Lucid's vehicles are now compatible with Tesla's Supercharger network, enhancing convenience for owners and potentially boosting sales [15] - The company has an Earnings ESP of +3.08% and a Zacks Rank of 3, with Q2 revenue estimated at $253.4 million, reflecting year-over-year growth of 26.4% [17] American Axle & Manufacturing Holdings, Inc. (AXL) - American Axle is advancing in the electric drive space and has a strong electrification portfolio, with key launches driving growth [18] - The company has an Earnings ESP of +17.59% and a Zacks Rank of 3, with Q2 earnings and revenues estimated at 13 cents and $1.51 billion, respectively [20]

Key Takeaways IRM is expected to post Q2 revenue growth and higher AFFO per share versus last year.Data center leasing is likely to boost performance amid strong connectivity and colocation demand.Higher interest expenses may have weighed on overall quarterly results.Iron Mountain Incorporated (IRM) is slated to release second-quarter 2025 results on Aug. 6, before the opening bell. The quarterly results are likely to display year-over-year growth in revenues and adjusted funds from operations (AFFO) per sh ...

Key Takeaways Jacobs is expected to report Q3 EPS of $1.56, down 20.4% YOY, on $3.07B in revenues, down 27.6%.Global macro headwinds, FX impact and inflation may weigh on the Infrastructure and PA Consulting segments.Cost streamlining initiatives could partially offset margin pressures from labor and IT investments.Jacobs Solutions, Inc. (J) is slated to report third-quarter fiscal 2025 results on Aug. 5, before the opening bell.In the last reported quarter, the company’s adjusted earnings topped the Zacks ...

Core Insights - Runway Growth Finance Corp. (RWAY) is expected to report second-quarter 2025 results on August 7, with anticipated revenue decline and earnings increase year-over-year [1][8] - The company has a weak earnings surprise history, lagging the Zacks Consensus Estimate in three of the last four quarters [2] Earnings & Sales Projections - The Zacks Consensus Estimate for RWAY's earnings is 39 cents, reflecting a 5.4% increase from the prior-year quarter [3] - The consensus estimate for sales is $34 million, indicating a slight decline [3] Factors Impacting Earnings - The Federal Reserve's decision to keep interest rates unchanged at 4.25-4.5% during Q2 2025 likely benefited RWAY's interest income due to higher loan yields [4] - RWAY has been experiencing rising expenses due to investments in venture growth stage companies, which are expected to have elevated operating costs in the second quarter [4] Earnings Whispers - The quantitative model does not predict an earnings beat for RWAY, as it lacks a positive Earnings ESP and a Zacks Rank better than 3 [5] - RWAY currently holds a Zacks Rank of 3 [6] Performance of Other Finance Stocks - Moody's reported adjusted earnings of $3.56 per share, exceeding the Zacks Consensus Estimate of $3.44, with an 8.5% year-over-year growth [7] - Moelis & Company reported adjusted earnings of 53 cents per share, significantly improving from 18 cents in the prior-year quarter, supported by revenue growth despite increased expenses [9]

The market expects Excelerate Energy (EE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be releas ...

Company Overview - Bitdeer Technologies Group (BTDR) is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year decline of 733.3% [3] - Revenues are anticipated to be $80.62 million, down 18.8% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 25.58% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bitdeer is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.51% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 3 [10][12] - Bitdeer has a Zacks Rank of 3, indicating a potential to exceed the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Bitdeer was expected to post a loss of $0.48 per share but actually reported a loss of -$0.37, achieving a surprise of +22.92% [13] - Over the past four quarters, Bitdeer has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Technology Services industry, Amprius Technologies (AMPX) is expected to report a loss of $0.08 per share, which represents a year-over-year change of +38.5% [18] - Amprius's revenue is projected to be $12.92 million, up 285.7% from the previous year, with a positive Earnings ESP of +4% [19][20]

Ellington Credit (EARN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the st ...

Gevo, Inc. (GEVO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 11, might help the stock move higher if these key numbers are better than expectatio ...